SOMERVILLE, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, and the Chan Zuckerberg Initiative (CZI) today announced a partnership to drive innovation in machine learning (ML) algorithms for single-cell analysis via support of the Open Problems in Single-Cell Analysis initiative. Starting with a collaboration in 2021 to host a multimodal data integration competition, CZI and Cellarity’s partnership has grown to support efforts that include the creation of unique benchmarking datasets to power competitions drawing thousands of participants and the creation and support of community-driven, open-source algorithm benchmarks hosted at Open Problems.
“Single-cell biology is at the forefront of biomedical research and data science. Now more than ever, we recognize the importance of benchmarks and challenges to help bring data science and cutting-edge computational approaches to single-cell biology,” said Jonah Cool, Ph.D., Senior Program Officer of the Single-Cell Biology program at the Chan Zuckerberg Initiative. “We are excited to again support Cellarity and Open Problems in Single Cell Analysis as we unravel the mysteries of the cell, moving beyond descriptive biology and into mechanistic understandings.”
Fabrice Chouraqui, Pharm.D., CEO of Cellarity and CEO-Partner at Flagship Pioneering, said, “At Cellarity, we are constantly pushing the boundaries of machine learning applications for single-cell analysis. We are proud to partner with CZI and Open Problems in Single-Cell Analysis to unlock new applications that enable us to create medicines more efficiently and bring innovations to patients faster. We are excited to build on our track record of success hosting machine learning competitions in 2021 and 2022 to, this year, challenge machine learning experts around the world to model simulated drug discovery experiments more efficiently.”
“There are more than 1,500 algorithms developed for single-cell data, and understanding the deep complexity of cells captured by single-cell technologies requires robustly evaluating the performance of these methods,” says Diogo Camacho, Ph.D., Vice President of Computational Biology at Cellarity. “It’s exciting to see Cellarity scientists partner with academic leaders around the world to develop fair and open benchmarks.”
For the first competition in 2021 featuring multimodal data integration, Cellarity collaborated with the Chan Zuckerberg Biohub San Francisco, Yale University, and Helmholtz Münich to generate the largest realistic benchmarking dataset currently available for multimodal single-cell data, defining three distinct tasks for multimodal single-cell data integration and metrics to evaluate them. The consortium hosted a second competition in 2022 that was powered by a new benchmarking dataset, a reformulation of the task metrics, and an extension to temporal dynamics modeling. The 2022 competition attracted more than 1,600 competitors on Kaggle and is, to the best of our knowledge, the largest single-cell competition ever conducted.
This year’s Kaggle competition will tackle a new challenge in single-cell data science and introduce another novel benchmark dataset to tackle problems in modeling cellular response to chemical perturbation. The objective is to develop methods that can generalize to unseen perturbations and cell types to enable scientists to overcome the practical and economic limitations of single-cell perturbation studies. The goal of this competition is to leverage advances in representation learning to unlock new capabilities bridging data science, machine learning, and computational biology.
Entries to the competition will be accepted until November 30, 2023. For more information, visit the competition page on Kaggle.
About the Chan Zuckerberg Initiative
The Chan Zuckerberg Initiative was founded in 2015 to help solve some of society’s toughest challenges — from eradicating disease and improving education, to addressing the needs of our communities. Through collaboration, providing resources and building technology, our mission is to help build a more inclusive, just and healthy future for everyone. For more information, please visit chanzuckerberg.com.
Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single-cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immunology. For more information, visit www.cellarity.com.
About Open Problems in Single-Cell Analysis
Open Problems in Single-Cell Analysis is a community-driven open-science initiative co-founded by scientists at Helmholtz Münich, Yale University, and the Chan Zuckerberg Biohub San Francisco and has grown to a global consortium of scientists spanning academia and industry. Open Problems aims to unite the machine learning and computational biology communities to drive innovation in single-cell analysis algorithms through the generation of transformative benchmarking datasets, hosting of international competitions, and development of open-source algorithm benchmarks. Learn more and get involved at https://openproblems.bio/.